| Title |
Amitriptyline versus placebo for major depressive disorder
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2012
|
| DOI | 10.1002/14651858.cd009138.pub2 |
| Pubmed ID | |
| Authors |
Claudia Leucht, Maximilian Huhn, Stefan Leucht |
| Abstract |
Amitriptyline is a tricyclic antidepressant that was synthesised in 1960 and introduced as early as 1961 in the USA, but is still regularly used. It has also been frequently used as an active comparator in trials on newer antidepressants and can therefore be called a 'benchmark' antidepressant. However, its efficacy and safety compared to placebo in the treatment of major depression has not been assessed in a systematic review and meta-analysis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Brazil | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 260 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| Germany | 2 | <1% |
| Unknown | 256 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 44 | 17% |
| Researcher | 35 | 13% |
| Student > Bachelor | 28 | 11% |
| Student > Ph. D. Student | 18 | 7% |
| Student > Postgraduate | 14 | 5% |
| Other | 48 | 18% |
| Unknown | 73 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 84 | 32% |
| Psychology | 23 | 9% |
| Nursing and Health Professions | 19 | 7% |
| Agricultural and Biological Sciences | 12 | 5% |
| Social Sciences | 10 | 4% |
| Other | 28 | 11% |
| Unknown | 84 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2023.
All research outputs
#6,564,179
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#8,256
of 13,156 outputs
Outputs of similar age
#62,465
of 287,251 outputs
Outputs of similar age from Cochrane database of systematic reviews
#111
of 197 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,251 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 197 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.